Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 53,811 shares, a drop of 85.3% from the October 15th total of 367,297 shares. Based on an average daily trading volume, of 166,740 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
FSNUY has been the topic of a number of recent research reports. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday, October 28th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company has a consensus rating of “Buy”.
Get Our Latest Research Report on Fresenius SE & Co.
Fresenius SE & Co. Stock Up 0.9%
Shares of FSNUY stock opened at $14.99 on Wednesday. The stock has a market cap of $33.77 billion, a P/E ratio of 14.71 and a beta of 0.63. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $15.94. The stock has a fifty day moving average price of $13.02 and a 200 day moving average price of $12.87. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97.
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.03. The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.51 billion. Fresenius SE & Co. had a net margin of 6.58% and a return on equity of 10.24%. Analysts predict that Fresenius SE & Co. will post 1.04 earnings per share for the current year.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.
Recommended Stories
- Five stocks we like better than Fresenius SE & Co.
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
